INTRODUCTION
The nicotinicoid receptors are a superfamily of ligand-gated ion channels that are essential mediators of fast neurotransmission at neuronal and neuromuscular synapses. In vertebrates, the major members of this ionotropic superfamily include the inhibitory receptors gated by glycine or ␥ -aminobutyric acid (GlyR and GABA A R, respectively) and the excitatory receptors gated by acetylcholine or serotonin (nAChR and 5HT 3 R, respectively). These receptors are assemblies arranged about a central pore that transiently opens upon the binding of agonist, allowing the passive diffusion of anions (GlyR and GABA A R) or cations (nAChR and 5HT 3 R). 1 , 2 Each pentameric receptor may be comprised of different gene products (eg, GlyR is composed of ␣ and ␤ subunits) and/or splice variants, mixed at different stoichiometries. The specifi c conductance properties of all channel types are defi ned by their composition, posttranslational modifi cations, and interaction with different modulatory ligands. Although this review focuses on the inhibitory receptors, some discussion of homologous excitatory receptors is unavoidable since the structure of a soluble acetylcholine binding protein (AChBP) that is a homolog of the extracellular domain (ECD) of nicotinicoid receptors has been resolved in crystallographic studies, 3 and the structure of isolated nAChR from Torpedo has been resolved by cryomicroscopy to 4 Å. 4 These structures provide an appropriate template for modeling all nicotinicoid receptors and have been extensively used by investigators to interpret and refi ne our understanding of these receptors. 5 Both GlyR and GABA A R are channels whose role in the central nervous system (CNS) of adults is to mediate inhi bitory neurotransmission by facilitating Cl -infl ux into neurons. 6 , 7 Each receptor type has a distinctive tissue distribution, with GlyRs being the primary target for inhibitory neurotransmission in the brainstem and spinal cord and GABA A Rs being more widely distributed throughout the CNS. However, mixed GABA-Gly synapses have been observed in many cell types. [8] [9] [10] [11] For example, both receptor types are found in the retina, where they function in rod photoreceptor development. 12 While the specifi c subunit composition of each receptor type may vary spatially and temporally, the inhibitory activities of the subtypes of both receptor classes are broadly similar. Typically, the multiple binding of agonists results in rapid channel opening, and prolonged ligand occupancy gives rise to receptor desensitization, a relatively long-lived state that is refractory to channel reactivation. Complex functional profi les of the receptors are generated by differential expression of subtypes and altered activities via subunit-specifi c allosteric modulation of the receptors (described below). Hence, each receptor subtype has distinct kinetics, conductance, and sensitivities to ligands, giving rise to receptors ' exquisite and differential sensitivities and activities.
GlyR and GABA A R are generally described as inhibitory neuroreceptors, because channel opening typically results in a hyperpolarizing inward Cl -fl ux. However, in embryonic neurons, the higher intracellular Cl -concentration results in Cl -effl ux upon GlyR and GABA A R activation and a strong excitatory suprathreshold depolarization that gates Ca 2+ infl ux and is hypothesized to guide neuronal development. 13 GABA is particularly important, as the hyperpolarizing activity of GABA A R in embryonic neurons provides most of the excitatory drive in early development. 14 Both glycinergic and GABAergic pathways have been shown to E354 be crucially involved in establishing early inhibitory networks. 15 In addition to their roles in neuronal development, both receptor types have been implicated in many channelopathies, as dysfunction of these receptors may lead to disease. 16 GlyR mutations play a role in diseases associated with a lack of motor control, such as spasticity and startle diseases. [17] [18] [19] Dysfunction of GABA A R-mediated inhibition has been implicated in many neurological and psychiatric conditions, including depression, affective disorders, and epilepsy. 20 , 21 GlyR was the fi rst neurotransmitter-gated ion channel isolated from mammals and was originally isolated by affi nity chromatography from rats as an assembly of 48 kD ␣ 1 and 58 kD ␤ subunits. 22 While ␣ subunits can form homooligomers, the stoichiometry of hetero-oligomers has recently been shown to be 2 ␣ 1 :3 ␤ . 23 To date, 4 different ␣ subunits ( ␣ 1 -4 ) and a single ␤ subunit have been identifi ed. The subunits comprising GABA A Rs are more numerous, with 19 different gene products among the 8 constituent subunit families, ␣ 1 -6 , ␤ 1 -3 , ␥ 1 -3 , ␦ , ⑀ , , , and 1 -3 (historically, GABA A Rs comprising subunits have been referred to as GABA C Rs), described to date (for more information, including sequence alignments, see the Cys-loop LigandGated Ion Channel database at http://www.ebi.ac.uk/ compneur-srv/LGICdb/LGICdb/cys-loop.php 24 ). The majority of GABA A Rs contain ␣ , ␤ , and ␥ subunits with a probable stoichiometry of 2 ␣ :2 ␤ :1 ␥ , with the ␣ and ␤ subunits necessary for GABA activation and the ␥ subunits required for benzodiazepine sensitivity. 25 
NICOTINICOID RECEPTOR TOPOLOGY AND STRUCTURE
For both types of channels, further structural and functional diversity is introduced by splice variants. Regardless of composition, all members of the nicotinicoid superfamily, including the excitatory nAChR and 5HT 3 R cation channels, share a common topology. The pore domain of each subunit contains 4 transmembrane (TM) segments, M1 to M4, and their connecting loops, with the 5 M2 amphiphilic helices defi ning the central pore. All 4 TM segments of each subunit are observed as membrane-spanning helices in electron crystallographic studies of nAChR isolated from Torpedo ray 4 (for an interactive display of this structure, see http://www.pdb.org/pdb/explore.do?structureId=2BG9). The large ECD of each pentameric receptor contains the binding site for its preferred agonist at specifi c interfaces between adjacent subunits. These domains also contain a conserved Cys-disulfi de separated by 13 residues (giving rise to the alternate nomenclature of " Cys-loop " superfamily). As mentioned above, the structure of AChBP has been determined 3 (for an interactive display of this structure, see http://www.pdb.org/pdb/explore.do?structureId=1I9B), and its structural homology to the ECD of nAChR was confi rmed in lysine scanning mutagenic studies, 26 suggesting that each ECD comprises a sandwich of ␤ -sheets with very little ␣ -helix. Furthermore, a chimera containing the AChBP and the pore domain of a 5HT 3A R retained activity, 27 showing that the AChBP structure can function as a modular ECD for the holoreceptor. The original AChBP crystals were grown in 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer, and HEPES was observed to bind to the nicotinamide binding site. The molecular details of HEPES binding were consistent with the agonist binding sites of homologous nicotinicoid receptors suggested by experi mental studies. This structural determination of a homolog of the ECD of nicotinicoid receptors has provided an essential template to allow investigators to rationally model the ligand binding domains of these receptors [28] [29] [30] [31] [32] For GlyR and GABA A R, the binding sites for agonists and antagonists reside at the interface between adjacent subunits, and this binding site is modeled as being defi ned by residues on 3 loops of 1 subunit and 3 loops from its neighbor. 23 , 28 Phylogenetic analysis of animal nicotinicoid receptors and their prokaryotic homologs (with unknown agonist specifi city) indicated that at least 1 aromatic residue is involved in ligand binding, with cation-pi interactions implicated in binding interactions. 33 GlyRs are gated by glycine, and ␤ -alanine and taurine are considered partial agonists. Strychnine is a selective competitive antagonist exhibiting the greatest potency toward most GlyR isoforms. For GABA A R, the preferred agonist is GABA, but the receptors are also activated by muscimol and antagonized by benzodiazepines (described in more detail below). Both receptors may be gated by ␤ -alanine and taurine, 34 and taurine plays an important role as agonist for either receptor in regions where both are coexpressed. 12 The selectivity of agonists for specifi c subunit composition may be exploited therapeutically. For example, the ␦ -containing GABA A R is highly expressed extrasynaptically in the thalamus and has a high affi nity for gaboxadol, which has effi cacy as a treatment for insomnia. 35 Given the homology between GlyR and GABA A R, Schmieden et al 36 substituted GABA A R residues for GlyR residues in the putative binding pocket of GlyR and successfully generated recombinant forms of GlyR that exhibited GABA-like agonist preferences. These studies indicated that the ECDs of these receptors share a common structure and elucidated some of the molecular details involved in the ligand binding pocket, as well as foreshadowing the capability wherein one could exploit knowledge of receptor structure and function to therapeutically target specifi c native and/or mutant receptor complexes for modulation.
The function of the inhibitory receptors may also be modulated by ions that interact with the ECD of the receptors. For E355 the GlyR, Zn 2+ has biphasic activity in that it potentiates activity of the receptor at submicromolar concentrations but is inhibitory at higher micromolar concentrations. 37 These concentration ranges are physiologically relevant, as zinc may be released into the synaptic cleft at fairly high levels. The inhibitory site was the fi rst to be identifi ed, 38 and subsequent studies identifi ed this inhibitory site as residing at subunit interfaces, with His107 of one subunit and His109 of the neighboring subunit forming a Zn 2+ coordination site. 30 Recently, the distinct site responsible for the potentiating Zn 2+ site in the ECD of GlyR has been elucidated. 39 Zn 2+ also has several discrete binding sites on the ECD of GABA A Rs that inhibit channel activity. 40 Extracellular pH also appears to modulate GlyR and GABA A R function via redox-sensitive sites in the ECD 41 and TM regions. 42 , 43 These studies show that the binding of small agonists and ions at sites in the ECD activate or modulate receptor function.
CHANNEL GATING AND ALLOSTERY
One of the controversies in nicotinicoid receptor (or, for that matter, any gated neuroreceptor) research is the molecular details of activation and desensitization: how does binding of an agonist at a distinct distant site in the subunit interface of the ECD transiently open a central conducting pore? While many models for channel gating have been proposed and some details have been elucidated, [44] [45] [46] [47] [48] [49] [50] the full molecular details remain unresolved. With respect to GlyR and GABA A R, allosteric coupling of binding and gating is apparently effected through interactions of residues on the membrane-proximal loops in the ECD with residues on the pre-TM1 and TM2-TM3 linker. [50] [51] [52] [53] [54] Recently, a chimera in which the ECD of ␣ 7 nAChR subunit was fused to the poreforming TM domain of ␣ 1 was shown to retain activity, albeit with altered kinetics such that the receptor opened slowly and did not desensitize to any great degree. 33 As discussed by the authors of this study, the functional coupling of distinct modular domains encompassing the ECD of the cationic nAChR with the TM domain of the inhibitory GlyR suggests a gating mechanism that is common to the entire nicotinicoid superfamily. Homologs of the nicotinicoid receptors have been identifi ed in prokaryotes, and it appears that the coupling of the ECD with the pore domain, and the channel-gating mechanisms of this receptor type, have been remarkably well conserved evolutionarily. 55 As alluded to above in discussions of the multiple states of the receptors (resting, open, and desensitized), the receptors are dynamic complexes with different allosteric states. 56 With respect to GABA A R and GlyR, the mobilities of distinct regions of these receptors are well documented in studies that examine the state-dependent accessibility of engineered sites of GABA A R residues [57] [58] [59] [60] [61] or GlyR [61] [62] [63] [64] [65] [66] [67] [68] residues to chemical modifi cations. Distinct structural rearrangements in GABA A R upon activation and antagonism were also observed in simultaneous electrophysiological studies and fl uorescence monitoring of site-specifi c labels. 69 Recently, spin labeling studies in which homomeric GlyR incorporating 5 symmetrically related nitroxides at a single site per subunit have also observed changes in the spin-spin distances in the resting and desensitized states (K.M. Stone, Z. Yang, M. Bonora, M. Cascio, and S. Saxena, unpublished data, 2006). In addition to agonists and competitive antagonists, the receptors also interact with a wide range of compounds that affect receptor function. The modulatory actions and allosteric effects of interactions with drugs, ligands, and other macromolecules are discussed in the following sections. These interactions are often complex and interdependent (eg, interactions of a receptor with one compound will alter the sensitivity and effects of interactions with other compounds).
LIPIDS, ANESTHETICS, AND NEUROSTEROIDS
All membrane proteins are intimately associated with the lipid bilayer in which they reside. The effects of lipids on membrane proteins, and of proteins on bilayer structure, has always been appreciated but has only recently been the focus of intense investigation. 70 , 71 While the modulatory effects of the lipid microenvironment on ion channel activity have been widely noted, they remain poorly understood. 72 , 73 The roles of lipids in the function of nicotinicoid receptors have been most extensively characterized for nAChR, 74 where there is an absolute requirement for cholesterol and negatively charged phospholipids for activity. Investigators have noted the effects of lipid composition on nAChR structure and function [75] [76] [77] and have mapped the contact regions of proteins with surrounding lipids. [78] [79] [80] [81] [82] [83] Given the homology of the nicotinicoid superfamily, many of the lipid-facing regions found for nAChR are postulated to be similar for GlyR and GABA A R.
The cholesterol content in membranes profoundly affects the physicochemical properties of the bilayer, and cholesterol content ' s role in lipid organization and human disease is well documented. 84 As described above, the cholesterol content in membranes is essential for nAChR activity. While some of the effects of cholesterol on receptor function may be due to cholesterol ' s role in altering the properties of the membrane sites, distinct sites of direct interaction with the nAChR have been broadly mapped. 81 , 85-87 The cholesterol content has been shown to modulate both GlyR activity 88 and GABA A R activity. 89 , 90 We found that purifi cation of active recombinant ␣ 1 GlyR homopentamers requires cholesterol to be present in proteoliposomes/detergent mixtures during all steps of purifi cation, suggesting that the interaction with cholesterol stabilizes the receptor. 91 The activity of some anesthetics has been proposed to be attributable to their partitioning into the lipid bilayer and altering the physicochemical properties of the bilayer. 92 , 93 However, the observed enantiomeric specifi city of some anesthetics in modulating ion channel activity argues for specifi c binding sites on these proteins in the membrane, though this does not rule out the potential contribution of a nonspecifi c lipid-based mechanism of action. 94 , 95 Volatile and intravenous anesthetics, as well as alcohols, modulate the activity of nicotinicoid receptors, potentiating GlyR and GABA A R at concentrations consistent with those used pharmacologically. [96] [97] [98] These compounds appear to bind in a discrete water-accessible cavity between the TM segments. 99 n -Alcohol potentiation of the receptors increases with increasing length of the alcohol until a cutoff is reached, and further increases give rise to reduced potentiation. 100 The location of the alcohol binding pocket was confi rmed by mutagenesis studies wherein the volume of side chains in TM segments M1, M2, and M3 that putatively defi ne the alcohol binding pocket was varied, altering the potency of the observed effects. 65 , 101 Studies conducted during gating and alcohol modulation of GABA A R also confi rm dynamic changes in the accessibility of select residues thought to defi ne this binding pocket. 102 , 103 Residues on the TM helix M4 are also involved in the response to anesthetics, as scanning tryptophan mutagenesis studies 104 and accessibility studies 66 showed that select residues of M4 of GABA A R play a role in this response. It has been hypothesized that a possible mechanism for anesthetic action is that the volume of the binding pocket expands and contracts during channel opening and closing, and this fi nding is supported by statedependent changes in accessibility to this putative pocket 65 ; occupancy of this pocket by anesthetics stabilizes the open state, giving rise to their potentiating effects.
In addition to cholesterol, other sterols have been noted to affect the activity of the inhibitory receptors. It was fi rst recognized that the general anesthetic effect of alphaxalone, a synthetic pregnane steroid, is via enhancing of GABA A R function by promoting longer open durations. 105 This modulation was also dependent on the cholesterol content of the membrane. 89 The enantiomeric-selective response of the receptors to steroid compounds suggests that specifi c binding sites for these compounds are present on the receptor, but the exact site of interaction has not been fully resolved. The binding site of alphaxalone has been suggested to be in the N-terminal half of M2 106 and in the pre-M1 region of the ␤ 2 subunit. 107 Another neurosteroid, pregnenolone, is a highly potent modulator of GABA A R-mediated neurotransmission. At higher concentrations it is considered GABAmimetic and directly activates the receptor. Pregnane and androstane steroids have also been shown to modulate GlyR in a subunit-specifi c manner. 108 Depending on dosage, neurosteroids can induce analgesic, anticonvulsant, anxiolytic, hypnotic, or sedative effects. 109 , 110 However, sulfated neurosteroids such as pregnenolone sulfate inhibit GABA A R activity, producing opposite effects.
OTHER DRUGS AND THERAPEUTICS
As described above, anesthetics, ethanol, and other n-alcohols potentiate GlyR and GABA A R. The nicotinicoid receptors are also involved in long-term effects of alcohol abuse, as well as addiction to nicotine and barbiturates. [111] [112] [113] [114] The role of GlyR in the development of alcohol addiction has recently been elucidated, as GlyRs in the nucleus accumbens appear to regulate extracellular dopamine levels. 115 , 116 Other drugs of abuse also interact with the inhibitory receptors. For example, ethanol, 117 cocaine, 118 and inhaled solvents 119 affect GlyR activity. GlyR and GABA A R are also targeted and modulated by various narcotics (eg, barbiturates) and therapeutic agents for the treatment of a wide range of psychiatric disorders such as anxiety and drug dependence. 32 , 96 , 100 , 120 In addition, GABA A R is the target for some drugs used in treating epilepsy. Antiepileptic drugs often involve blockage of Na + or K + channels, but antiepileptic effects are also mediated via enhancement of the inhibitory activity of GABA A R and/or by effects on glycine systems. 121 , 122 For example, the barbiturate phenobarbital increases the channel mean open time of GABA A R. Initially, barbiturates were used as anxiolytic and anticonvulsant agents, as well as intravenous anesthetics. However, because of the risk of dangerous respiratory depression, these barbiturates have been preferentially replaced with benzodiazepines. Among the many drugs that interact with glycinergic and GABAergic systems, the 2 drug classes that have been best characterized at a structural and functional level are the benzodiazepines and convulsant toxins such as picrotoxin. The interactions of these compounds with GABA A R and GlyR are described briefl y below.
Benzodiazepines are the most widely used hypnotic compounds (this family includes diazepam, more commonly known as valium) and bind to a site at the interface of ␣ and ␥ subunits, distinct from the GABA site. 123 These compounds do not open the channel, but binding allosterically modulates ligand affi nity and increases the opening frequency of GABA A R, inducing anxiolytic and sedative effects. 124 Inverse agonists acting at the same binding site are drugs with anxiogenic and convulsant properties (eg, ␤ -carbolines). While benzodiazepines are effective sedatives and have been used in the treatment of some forms of epilepsy, prolonged use leads to tolerance, and this class of compounds is addictive. 113 In accessibility studies, the binding of diazepam in the ECD of GABA A R altered the accessibility of select residues in the membrane-spanning M3 segment, suggesting that the allosteric modulation effected by benzodiazepine binding extends into the membrane-spanning domain, giving rise to a conformational state that is distinct from the resting and open state of the receptor. 58 The convulsant plant alkaloid picrotoxin inhibits both GABA A R and GlyR, but GABA A R is generally more sensitive to this alkaloid, having sensitivities in the low micromolar range. Picrotoxin binds with lower affi nity to the ␣ / ␤ heteromers of GlyR (as opposed to the ␣ homomers of this channel, which have similar affi nities as GABA A R) and is thought to bind in the central pore of the receptors. The binding is of higher affi nity to the closed channel form of the receptor, thereby decreasing the equilibrium constant for channel opening. 125 This is supported by recent studies, wherein binding of picrotoxin in the channel mediated allosteric conformational changes in the M2-M3 loop of GlyR. 64 These changes to loop accessibility could not be replicated in studies in the presence or absence of glycine, suggesting a complex global allosteric modulation of the receptor in response to picrotoxin binding and underscoring the critical role of the M2-M3 loop in coupling agonist binding to channel gating.
OTHER PROTEINS
In addition to interactions with small molecules that alter the activity of GlyR and GABA A R, their activity may be directly or indirectly modulated by other proteins. These interactions are most typically mediated via interactions of other proteins with the large intracellular loop between the third and fourth TM segments. This cytoplasmic linking region between M3 and M4 is the least evolutionarily conserved region among nicotinicoid family members. This loop has been shown to be involved in interactions with other proteins that result in receptor crosstalk, subcellular targeting and clustering, and activity modulation. [126] [127] [128] [129] For example, GlyRs may be functionally modulated via interactions with G-protein ␤ ␥ subunits, 130 and GABA A Rs and dopamine D5 receptors crosstalk via direct protein-protein interactions. 131 One of the most common protein-protein interactions that affect receptor function is that of neuroreceptors with kinases or phosphatases to alter their phosphorylation state. The phosphorylation of neurotransmitter-gated channels can have short-and long-term effects and has been implicated in forms of synaptic plasticity. The effects of phosphorylation on GlyR and GABA A R function are complex and depend on both the subunit composition and the specifi c site(s) of phosphorylation. To date, all phosphorylation sites of nicotinicoid receptors have been mapped to the M3-M4 linker region. Multiple isoforms of kinases and phosphatases have been implicated as affecting receptor activity, but these effects may be directly due to the modulatory effects attributable to phosphorylation on channel activity, or be due to indirect effects, such as targeting receptorassociated proteins. 132 , 133 GlyR activity is enhanced in vivo by cAMP-dependent protein kinase phosphorylation, 134 and tyrosine kinases enhance GlyR activity in rat hippocampal neurons. 135 Various protein kinase C isoforms have been shown to modulate GABA A R conductance, their sensitivity to allosteric effectors, and their traffi cking. 136 With respect to the direct effects of phosphorylation, protein kinase C phosphorylates the ␣ 1 subunit of GlyR at a single site, potentiating its activity. 137 One recent example of the profound effects of phosphorylation on receptor function is the inhibitory effects of phosphorylation of ␣ 3 GlyR subunits. Prostaglandin E 2 , a key mediator of infl ammatory pain sensitization, induces phosphorylation of ␣ 3 subunits of GlyR, 138 and this inhibition underlies central infl ammatory pain sensitization. These studies also identify GlyR as a new therapeutic target for analgesia since ␣ 3 GlyR is in spinal cord dorsal horn, where nociceptive afferents terminate, 139 and underscore the utility in targeting inhibitory ion channels as therapeutic targets. 140 , 141
CONCLUSIONS
Given their role as essential mediators of fast inhibitory neurotransmission in the CNS, the structure, function, and pharmacology of GABA A R and GlyR have been extensively studied. These channels are also the targets for many drugs of abuse, and dysfunctions of these receptors underlie many channelopathies. The recent determination of the homologous structures of the soluble AChBP and the fulllength nAChR has provided researchers with the requisite tools for interpreting the large body of experimental data available and modeling GABA A R and GlyR structure and dynamics. These models provide us with the potential to develop and exploit novel subunit-specifi c therapeutics to modulate the activity of targeted subsets of GABA A R and GlyR in treating disease.
